Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. by Smith, RL et al.
CONCISE COMMUNICATION
Association of Toll-like receptor 4 (TLR4) with chronic plaque type
psoriasis and psoriatic arthritis
Rh. Ll. Smith1,2 • H. L. He´bert1,2 • J. Massey2 • J. Bowes2 • H. Marzo-Ortega3 •
P. Ho4 • N. J. McHugh5 • J. Worthington2 • A. Barton2,6 • C. E. M. Griffiths1 •
R. B. Warren1
Received: 15 July 2015 / Revised: 3 January 2016 /Accepted: 8 January 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Family studies have provided overwhelming
evidence for an underlying genetic component to psoriasis.
Toll-like receptors (TLRs) are key transmembrane proteins
in both the innate and adaptive immune responses which
are known to be integral processes in psoriasis. Recent
functional studies support this notion having suggested a
role for TLR4 in the pathogenesis of psoriasis. Furthermore
a missense polymorphism in the TLR4 gene has been
associated with a number of autoimmune conditions,
including Crohn diseases, making TLR4 a viable candidate
gene for investigation. The aim of this study was to
investigate polymorphisms across the TLR4 region with a
high-density single nucleotide polymorphism (SNP) panel
in a large cohort of patients with chronic plaque type
psoriasis. Twenty SNPs were successfully genotyped using
Sequenom iPLEX Gold platform in 2826 UK chronic
plaque type psoriasis patients including subgroup data on
presence of confirmed psoriatic arthritis (n = 1839) and
early-onset psoriasis (n = 1466) was available. Allele
frequencies for psoriasis patients were compared against
imputed Wellcome Trust Case Control Consortium con-
trols (n = 4861). Significant association was observed
between a missense variant rs4986790 of TLR4
(Asp229Gly) and plaque type psoriasis (p = 2 9 10-4)
which was also notable in those with psoriatic arthritis
(p = 2 9 10-4) and early-onset psoriasis (p = 8 9 10-4).
We present data suggestive of an association between a
functional variant and an intronic variant of TLR4 and
chronic plaque type psoriasis and psoriatic arthritis. How-
ever, validation of this association in independent cohorts
will be necessary.
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Introduction
Family studies have provided incontrovertible evidence in
support of an underlying genetic component to the aetiol-
ogy of psoriasis. Recent meta-analyses of genome-wide
association studies [14–16] and other high-density single
nucleotide polymorphism (SNP) panel data [17] have
confirmed 41 genetic loci in psoriasis yet it is widely
accepted that a considerable portion of the disease’s heri-
tability remains unidentified. Research focusing on the
immunological processes underlying psoriasis has also
provided an invaluable insight into its pathogenesis. Toll-
like receptors (TLRs) are transmembrane proteins
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expressed on immune cells that recognise conserved
regions of both endogenous and exogenous molecules as
part of the innate and adaptive immune responses. Cru-
cially, TLRs are expressed in the skin and are differentially
expressed in involved psoriasis skin when compared to
uninvolved skin [2, 4]. Additionally, recent studies of
imiquimod psoriasis mouse models have shown TLR-de-
pendent pathways to be key in both the formation [7] and
maintenance [19] of psoriasis plaques.
Toll-like receptor 4 is speculated to be a trigger of
apoptosis and interacts with TLR2 in the autoimmune
pathway. Furthermore, a recent study has demonstrated an
increase in TLR4 expression on peripheral blood
mononuclear cells of psoriasis patients compared to con-
trols [6]. Polymorphisms within TLR4 have been associated
with a number of autoimmune conditions, genetically
linked to psoriasis, including Crohn disease [13], vitiligo
[10] and ulcerative colitis [13] as well as a wide range of
other diseases including Behcet’s involving arthritis [8],
atherosclerosis [5] and endotoxin hyporesponsiveness [1].
Therefore, due to the increasing evidence suggestive of a
role for TLR4 in the pathogenesis of psoriasis, we inves-
tigated polymorphisms across the gene with a high-density
SNP panel in a cohort of 2826 UK patients with chronic
plaque type psoriasis.
Materials and methods
Of these patients, 1839 had confirmed psoriatic arthritis
with the status in the remainder unknown. Age of onset
data was available for 2137 patients with 1466 defined as
early-onset (age of onset \40 years, mean 20.8 ± SD
9.8 years, range 0–39 years); 671 as late-onset (age of
onset C40 years, mean 50.6 ± SD 9.1 years, range
40–81 years) and 689 where the age of onset was
unknown. The early-onset cohort consisted of 861 PsA
cases (58.7 %), whilst the late-onset cohort consisted of
423 PsA cases (63.0 %).
A panel of 22 SNPs were selected across the TLR4
region (inclusive of 10 kbp up and downstream) including
tagging SNPs (r2[ 0.9), previously associated markers
and proxy markers in case of SNP failure using the Tagger
application within Haploview [3]. This panel of SNPs
captured 97 % of alleles with MAF[ 1 % (HapMap Phase
III Caucasian population, Build 36 database, May 2010).
In total, 2983 UK chronic plaque type psoriasis patients
were genotyped using a Sequenom MassArrayTM plat-
form and iPLEX Gold chemistry. Quality control (QC) of
the genotyping included removal of samples and markers
with a success rate\80 %, a minor allele frequency\1 %,
or a Hardy–Weinberg equilibrium p value\0.0001. Con-
trol information on these loci was obtained from
imputation of WTCCC GWAS control data incorporating
2889 samples from the 1958 British Birth Cohort (1958BC)
and 2834 samples from the UK Blood Services collection
(NBS) [18] using IMPUTE2 algorithm [9]. Statistical
analysis of the data was performed using the PLINK
(v1.07) statistical software package [12], using an allelic
association test.
Results
Twenty SNPs (Table 1) were successfully genotyped (two
assays failed due to poor cluster plots: rs10983755 and
rs1927911) in 2826 UK chronic plaque type psoriasis
patients (success rate = 94.7 %) including those with
confirmed psoriatic arthritis (n = 1839) and those known
to be early-onset (n = 1466) although these groups were
not mutually exclusive. Following imputation of the
WTCCC control cohort and QC, allele frequencies were
compared against a total of 4861 imputed controls with
information scores greater than 0.97 at each loci.
Significant association was observed in patients with
psoriasis at 2 of the 20 SNPs analysed when implementing
a Bonferroni adjusted significance threshold of p\ 0.0025
(rs12344353 p = 5 9 10-4; rs4986790 p = 2 9 10-4;
italic rows Table 1). However, when accounting for link-
age disequilibrium between the markers (independent sig-
nals between SNPs defined as r2\ 0.4) and retaining the
most significant SNP, only rs4986790 remained significant
(r2 of 0.96 with rs12344353) with risk conferred by car-
riage of the minor allele (p = 2 9 10-4; OR = 1.30, 95 %
CI 1.13–1.48, Table 1). This was confirmed when condi-
tioning a logistic regression analysis of all other markers on
rs4986790 revealing there to be no significant associations
at the defined threshold (data not shown).
Notably, rs4986790 is a missense variant located in exon
3 of TLR4 (chromosome 9) and encodes an aspartic acid to
glycine substitution (Asp229Gly). This particular poly-
morphism has been shown to interrupt TLR4-mediated
lipopolysaccharide signalling in mice and further alters
lipopolysaccharide responsiveness in humans—thereby
altering their ability to respond to environmental stressors
[1]. In light of this, it is interesting to consider whether this
variant may have a role in different manifestations of the
disease, such as psoriatic arthritis and early onset compared
to late-onset, as psoriasis is known to have a wide range of
environmental triggers, and the increased minor allele
frequency within the patients—which is postulated to drive
this altered response to lipopolysaccharide—would support
such a hypothesis.
Variant rs4986790 showed strongest evidence of asso-
ciation within those patients with confirmed psoriatic
arthritis (n = 1839, p = 2 9 10-4, Table 1) whereas no
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Table 1 Association of polymorphisms within the toll-like receptor 4 gene region with clinical subtypes of psoriasis
SNP Chr 9bp position A1/A2 Function Imputed controls (n = 4861) Patients with psoriasis (n = 2826)
MAF Imp.Info. score MAF Allelic p (SE) OR (95 % CI)
rs10818070 119496316 A/G Intergenic 0.07 1.000 0.08 0.0419 (0.06) 1.13 (1.01–1.28)
rs10759930 119501442 T/C Upstream 0.38 1.000 0.36 0.0360 (0.03) 0.93 (0.87–1.00)
rs2737191 119502536 G/A Upstream 0.29 1.000 0.29 0.6362 (0.04) 1.02 (0.95–1.09)
rs10116253 119504141 C/T Upstream 0.25 0.999 0.26 0.7027 (0.04) 1.02 (0.94–1.09)
rs10759932 119504965 C/T Upstream 0.13 0.999 0.14 0.1231 (0.05) 1.08 (0.98–1.19)
rs12344353 119508470 C/T Intronic 0.06 0.998 0.07 0.0005 (0.07) 1.27 (1.11–1.45)
rs11536871 119510319 C/A 50 UTR/Intronic 0.04 1.000 0.04 0.1132 (0.08) 1.14 (0.97–1.34)
rs11536878 119511374 A/C Intronic 0.12 1.000 0.12 0.3100 (0.05) 0.95 (0.86–1.05)
rs1927907 119512585 T/C Intronic 0.13 0.997 0.14 0.1468 (0.05) 1.07 (0.98–1.18)
rs2149356 119514020 T/G Intronic 0.31 0.997 0.33 0.0118 (0.04) 1.10 (1.02–1.17)
rs4986790 119515123 G/A Missense 0.05 1.000 0.07 0.0002 (0.07) 1.30 (1.13–1.48)
rs7873784 119518757 C/G 30 UTR 0.16 0.998 0.15 0.5298 (0.05) 0.97 (0.89–1.06)
rs1927906 119519936 C/T Downstream 0.09 1.000 0.11 0.0053 (0.06) 1.17 (1.05–1.30)
rs1554973 119520633 C/T Downstream 0.25 1.000 0.26 0.1249 (0.04) 1.06 (0.98–1.14)
rs7044464 119521218 A/T Downstream 0.16 0.999 0.15 0.6902 (0.05) 0.98 (0.90–1.08)
rs7037225 119523460 T/C Downstream 0.15 1.000 0.16 0.0958 (0.05) 1.08 (0.99–1.18)
rs913930 119523830 G/A Downstream 0.37 1.000 0.37 0.7308 (0.03) 1.01 (0.95–1.08)
rs2183016 119525036 C/A Intergenic 0.16 1.000 0.15 0.5178 (0.05) 0.97 (0.89–1.06)
rs1927905 119525129 C/T Intergenic 0.06 1.000 0.05 0.2272 (0.07) 0.91 (0.79–1.06)
rs10759934 119528817 T/A Downstream 0.48 0.972 0.47 0.0622 (0.03) 0.94 (0.88–1.00)
SNP PSA confirmed patients (n = 1839) Early-onset psoriasis (n = 1466) Late-onset psoriasis (n = 671)
MAF Allelic p (SE) OR (95 % CI) MAF Allelic p (SE) OR (95 % CI) MAF Allelic p (SE) OR (95 % CI)
rs10818070 0.09 0.0272 (0.07) 1.17 (1.02–1.34) 0.09 0.0269 (0.08) 1.18 (1.02–1.37) 0.08 0.5374 (0.11) 1.07 (0.87–1.32)
rs10759930 0.36 0.0148 (0.04) 0.91 (0.84–0.98) 0.37 0.3513 (0.04) 0.96 (0.88–1.05) 0.36 0.2098 (0.06) 0.93 (0.82–1.04)
rs2737191 0.29 0.7939 (0.04) 1.01 (0.93–1.10) 0.29 0.9495 (0.05) 1.00 (0.91–1.09) 0.30 0.5233 (0.06) 1.04 (0.92–1.18)
rs10116253 0.26 0.2268 (0.04) 1.06 (0.97–1.15) 0.25 0.6751 (0.05) 0.98 (0.89–1.08) 0.25 0.9297 (0.07) 0.99 (0.87–1.13)
rs10759932 0.14 0.0548 (0.06) 1.11 (1.00–1.24) 0.13 0.4063 (0.06) 1.05 (0.93–1.19) 0.14 0.3620 (0.08) 1.08 (0.91–1.28)
rs12344353 0.07 0.0007 (0.08) 1.30 (1.12–1.51) 0.07 0.0009 (0.08) 1.32 (1.12–1.56) 0.07 0.0754 (0.12) 1.23 (0.98–1.55)
rs11536871 0.04 0.1840 (0.10) 1.14 (0.94–1.37) 0.05 0.0755 (0.10) 1.20 (0.98–1.47) 0.04 0.9280 (0.15) 1.01 (0.76–1.36)
rs11536878 0.12 0.8061 (0.06) 0.99 (0.88–1.11) 0.11 0.1440 (0.07) 0.91 (0.80–1.03) 0.12 0.4645 (0.09) 0.94 (0.78–1.12)
rs1927907 0.14 0.0765 (0.06) 1.11 (0.99–1.23) 0.14 0.4211 (0.06) 1.05 (0.93–1.19) 0.14 0.4621 (0.09) 1.07 (0.90–1.26)
rs2149356 0.34 0.0042 (0.04) 1.13 (1.04–1.22) 0.33 0.1048 (0.05) 1.08 (0.98–1.18) 0.33 0.1741 (0.06) 1.09 (0.96–1.23)
rs4986790 0.07 0.0002 (0.08) 1.33 (1.14–1.55) 0.07 0.0008 (0.08) 1.33 (1.13–1.57) 0.07 0.0181 (0.12) 1.31 (1.05–1.65)
rs7873784 0.16 0.7570 (0.05) 1.02 (0.92–1.13) 0.14 0.0531 (0.06) 0.89 (0.79–1.00) 0.16 0.4379 (0.08) 1.06 (0.91–1.24)
rs1927906 0.11 0.0047 (0.06) 1.20 (1.06–1.36) 0.11 0.0156 (0.07) 1.18 (1.03–1.36) 0.11 0.0630 (0.09) 1.19 (0.99–1.44)
rs1554973 0.27 0.0251 (0.04) 1.10 (1.01–1.20) 0.25 0.7596 (0.05) 1.02 (0.92–1.12) 0.27 0.0660 (0.07) 1.13 (0.99–1.28)
rs7044464 0.16 0.7371 (0.05) 1.02 (0.92–1.13) 0.14 0.1082 (0.06) 0.91 (0.81–1.02) 0.16 0.4379 (0.08) 1.06 (0.91–1.24)
rs7037225 0.17 0.0814 (0.05) 1.10 (0.99–1.22) 0.16 0.2350 (0.06) 1.07 (0.96–1.20) 0.17 0.2129 (0.08) 1.10 (0.95–1.29)
rs913930 0.37 0.9862 (0.04) 1.00 (0.92–1.08) 0.37 0.8602 (0.04) 1.01 (0.92–1.10) 0.36 0.8490 (0.06) 0.99 (0.88–1.11)
rs2183016 0.16 0.7878 (0.05) 1.01 (0.91–1.13) 0.14 0.0577 (0.06) 0.89 (0.79–1.00) 0.16 0.4963 (0.08) 1.06 (0.90–1.23)
rs1927905 0.05 0.2980 (0.09) 0.91 (0.77–1.08) 0.05 0.1637 (0.10) 0.87 (0.72–1.06) 0.05 0.8037 (0.13) 0.97 (0.75–1.25)
rs10759934 0.47 0.2435 (0.04) 0.96 (0.88–1.03) 0.47 0.1281 (0.04) 0.94 (0.86–1.02) 0.48 0.6212 (0.06) 0.97 (0.87–1.09)
PS psoriasis patients, PSA psoriatic arthritis, Chr 9 chromosome 9, Bp base pairs, SE standard error, Imp.Info. Score imputation information
score, MAF minor allele frequency, 95 % CI 95 % confidence interval, OR odds ratio
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association was observed when comparing those without
definitive information on presence of psoriatic arthritis
against controls (n = 987 patients, p = 0.0462,
OR = 1.22, 95 % CI 1.00–1.49). However, when the
dataset was dichotomised according to age of onset, the
early-onset cohort was significantly associated with
rs4986790 (p = 8 9 10-4, OR = 1.33; 95 % CI
1.13–1.57, Table 1), but the late-onset cohort was not
significant at the adjusted threshold (p = 0.0181,
OR = 1.31 95 % CI 1.05–1.65). Given that the proportion
of confirmed PsA cases in each dichotomised cohort was
roughly the same, these results appear to suggest that PsA
is not driving this association. However, the lack of asso-
ciation in late-onset psoriasis could be due to lack of power
caused the low sample size of the cohort overall (n = 671)
compared to early-onset psoriasis (n = 1466), as well as
the lower number of confirmed PsA samples (n = 423 vs
861).
Discussion
In support of the data, a recent investigation of functional
polymorphisms within TLR2 and 4 reported an increased
frequency of rs4986790 SNP in Turkish vitiligo patients
(n = 100) when compared to healthy controls (n = 100)
with a similar minor allele frequency in the control cohorts
of both studies [10]. Furthermore, there is speculation that
these diseases are genetically linked with a recent meta-
analysis reporting the diseases to harbour common sus-
ceptibility loci in the Chinese Han population—predomi-
nantly within the HLA region on chromosome 6 [20]. A
meta-analysis of other autoimmune conditions linked to
psoriasis including Crohn disease and ulcerative colitis also
found the minor allele of rs4986790 to confer increased
disease risk [13].
It is worth noting that to date, large genome-wide
association and high-density SNP panel studies which
include rs4986790 are yet to report any significant asso-
ciation with psoriasis or psoriatic arthritis. This could be
due to issues in the past with heterogeneous cohorts, as
different manifestations of psoriasis such as chronic plaque
and generalised pustular type are known to have different
genetic signatures [11]. Another explanation is that past
failures to find an association could just be an artefact of
random sampling. Furthermore, a recent study mapping
cis-acting expression quantitative trait loci (eQTLs) in
psoriasis using normal skin from 57 healthy controls, and
both involved and uninvolved skin from 53 psoriasis
patients did not report any significant associated SNPs
tagging TLR4 eQTLs in their analysis (p\ 9 9 10-7) [17].
Additionally, we have previously reported an association
between TLR4 loci (rs10759932; rs7044464; rs752998) and
early-onset psoriasis (age of onset \40 years) in 664
patients and 566 healthy population based controls. We
were able to replicate the associations in this study
although the associated rs4986790 SNP was different to
that tested in the previous study (unpublished data).
Therefore the associations reported in our data should be
treated with caution. Nonetheless, it is of significant
interest that a functional missense variant in TLR4, known
to be associated with conditions genetically linked to
psoriasis, shows significant association with psoriasis and
psoriatic arthritis in this study. Validation of these associ-
ations would be crucial in confirming any association of
TLR4 with psoriasis and/or psoriatic arthritis with partic-
ular focus given to accurate phenotyping; including of age
of onset and associated presence or absence (confirmed by
a rheumatologist) of arthritis [2, 4, 6].
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